Edwards Lifesciences CorporationEWNYSE
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
1.63%
↓ 40% below average
Average (39q)
2.73%
Historical baseline
Range
High:12.49%
Low:-7.04%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 1.63% |
| Q2 2025 | 8.48% |
| Q1 2025 | -6.09% |
| Q4 2024 | 6.99% |
| Q3 2024 | -7.04% |
| Q2 2024 | 6.19% |
| Q1 2024 | 6.03% |
| Q4 2023 | -0.29% |
| Q3 2023 | -0.37% |
| Q2 2023 | -6.70% |
| Q1 2023 | 12.49% |
| Q4 2022 | -0.60% |
| Q3 2022 | -6.86% |
| Q2 2022 | 9.71% |
| Q1 2022 | -1.80% |
| Q4 2021 | -2.18% |
| Q3 2021 | 5.64% |
| Q2 2021 | 8.84% |
| Q1 2021 | 5.77% |
| Q4 2020 | 0.10% |
| Q3 2020 | 7.36% |
| Q2 2020 | -2.83% |
| Q1 2020 | -3.35% |
| Q4 2019 | -0.82% |
| Q3 2019 | 1.88% |
| Q2 2019 | 11.96% |
| Q1 2019 | 5.09% |
| Q4 2018 | 0.80% |
| Q3 2018 | 5.00% |
| Q2 2018 | 7.61% |
| Q1 2018 | -2.32% |
| Q4 2017 | 2.59% |
| Q3 2017 | 6.32% |
| Q2 2017 | 4.43% |
| Q1 2017 | 12.01% |
| Q4 2016 | 1.68% |
| Q3 2016 | 0.09% |
| Q2 2016 | 10.25% |
| Q1 2016 | 4.28% |
| Q4 2015 | -2.77% |